SMARCA2 and neoplasm: The main mechanism of action is degradation of SMARCA2 and SMARCA4, blocking access to chromatin, compression of chromatin around the core enhancers of AR, FOXA1, ERG, and MYC, and transcription factors are prevented from binding to cancer-driving enhancers, thereby attenuating the pro-oncogenic factor transcriptional program (135).AU-15330 is effective in prostate cancer xenograft models in inhibiting tumor growth and synergizes with the AR antagonist enzalutamide (135).